9:50 PM
 | 
Sep 24, 2008
 |  BC Extra  |  Company News

Dyax submits DX-88 BLA

Dyax (NASDAQ:DYAX) completed submission of a rolling BLA for DX-88 ecallantide to treat hereditary angioedema (HAE). Dyax requested...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >